

Curriculum Vitae
Sarwa Darwish Murad

Personal Information

Place of birth Baghdad, Iraq
Citizenship Dutch, American

Present Academic rank and position

Gastroenterologist/ Hepatologist, Department of Gastroenterology and Hepatology, Erasmus University Medical Center (Erasmus MC), Rotterdam, the Netherlands

Medical Education

1997 – 2004 Medical school at Erasmus University Rotterdam (EUR)
1999 – 2002 Master of Science in Health Services Research at the Netherlands Institute for Health Sciences (NIHES)
2004 – 2007 Ph.D at the Department of Gastroenterology and Hepatology, Erasmus MC
2007 – 2010 Residency at Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
2011 – 2016 Clinical Fellowship Gastroenterology and Hepatology, Erasmus MC

Degrees

June 26 2002 MSc (Health Services Research)
March 19 2004 M.D.
November 21 2008 Ph.D. (Thesis: Budd-Chiari Syndrome: New insights in pathogenesis, etiology and management)

Previous professional positions and appointments

1999 – 2002 Master of Science student at Department of Public Health, EUR
2001 Master of Science student at Harvard School of Public Health, Boston, MA, USA
2002 – 2007 PHD student, methodology coordinator of the European Network for Vascular disorders of the liver (EN-Vie)
2004 Research trainee at the Physiology and Imaging Research Laboratory, Mayo Clinic, Rochester, MN, USA
2005 Research collaborator at Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
2010 – 2011 Research fellowship at Division of Transplantation Surgery at Mayo Clinic, Rochester, MN, USA

Research grants

2010 AASLD (American Association for the Study of Liver Diseases) / LIFER Clinical and Translational Research Fellowship in Liver Diseases Award. Project: Efficacy of Neoadjuvant Chemoradiotherapy Followed by Liver Transplantation for Hilar Cholangiocarcinoma: a Multi-Center Review. 75K
2004 NWO Mosaic Personal PhD Research Grant (NWO; 2004/02324/AB). Project: "Fibrin Homeostasis in Budd-Chiari Syndrome: a Paradigm for Organ-Specific Thrombosis?" 180K
2003 Stichting de Drie Lichten (07/03 GFJ/mk). Project: Aspects of Microvasculature of the Liver in Budd-Chiari Syndrome- a Radiological and Histological Evaluation of a Rat Model. 3K
2003 NWO project grant (NWO; 2003/06549/CPI). Project: Aspects of the Microvasculature of the Liver in Budd-Chiari Syndrome-

2003

a Radiological and Histological Evaluation of a Rat Model.
4.2K
Netherlands Society of Hepatology (NVH). Project: EN-Vie
methodology. 2.5K

Publications

Original articles (chronological order)

1. **Darwish Murad S**, Fidler JL, Poterucha JJ, Sanchez W, Jowsey SG, Nagorney D, Rosen CB, Heimbach JK. *Long-term clinical and radiological follow-up of living liver donors. Accepted for publication*, Liver Transplantation 2016. (IF 4.2)
2. **Darwish Murad S**, Metselaar HJ. *The invasion of fatty liver disease in liver transplantation*. Transpl Int. 2015 Oct 24. doi: 10.1111/tri.12707. [Epub ahead of print] (IF 2.6)
3. Hofman A, Brusselle GG, **Darwish Murad S**, van Duijn CM, Franco OH, Goedegebure A, Ikram MA, Klaver CC, Nijsten TE, Peeters RP, Stricker BH, Tiemeier HW, Uitterlinden AG, Vernooij MW. *The Rotterdam Study: 2016 objectives and design update*. Eur J Epidemiol. 2015 Sep 19. [Epub ahead of print]. (IF 5.3)
4. Bhat M, Hathcock M, Kremers WK, **Darwish Murad S**, Schmit G, Martenson J, Alberts S, Rosen CB, Gores GJ, Heimbach J. *Portal vein encasement predicts neoadjuvant therapy response in liver transplantation for perihilar cholangiocarcinoma protocol*. Transpl Int. 2015 Jul 16. doi: 10.1111/tri.12640. [Epub ahead of print] (IF 2.6)
5. Koehler EM, Plompen EP, Schouten JN, Hansen BE, **Darwish Murad S**, Taimr P, Leebeek FW, Hofman A, Stricker BH, Castera L, Janssen HL. *Presence of Diabetes Mellitus and Steatosis is Associated with Liver Stiffness in a General Population: The Rotterdam Study*. Hepatology. 2015 Jul 14. doi: 10.1002/hep.27981. [Epub ahead of print] (IF 11.4)
6. Plompen EP, **Darwish Murad S**, Hansen BE, Loth DW, Schouten JN, Taimr P, Hofman A, Uitterlinden AG, Stricker BH, Janssen HL, Leebeek FW. *Prothrombotic Genetic Risk Factors are associated with an Increased Risk of Liver Fibrosis in the General Population: The Rotterdam Study*. J Hepatol. 2015 Jul 27. pii: S0168-8278(15)00517-6. doi: 10.1016/j.jhep.2015.07.026. [Epub ahead of print] (IF 11.3)
7. Plompen EP, Valk PJ, Chu I, **Darwish Murad S**, Plessier A, Turon F, Trebicka J, Primignani M, Garcia-Pagan JC, Valla DC, Janssen HL, Leebeek FW. *Somatic Calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis*. Haematologica. 2015 Feb 14. pii: haematol.2014.120857. (IF 5.8)
8. Plompen EP, Hansen BE, Schouten JN, **Darwish Murad S**, Loth DW, Brouwer WP, Isaacs A, Taimr P, Hofman A, van Duijn CM, Uitterlinden AG, Stricker BH, Leebeek FW, Janssen HL. *Interferon Gamma receptor 2 gene variants are associated with liver fibrosis in the general population: the Rotterdam Study*. Gut 2015 Apr;64(4):692-4. (IF 13.3)
9. Hofman A, **Darwish Murad S**, van Duijn CM, Franco OH, Goedegebure A, Ikram MA, Klaver CC, Nijsten TE, Peeters RP, Stricker BH, Tiemeier HW, Uitterlinden AG, Vernooij MW. *The Rotterdam Study: 2014 objectives and design update*. Eur J Epidemiol. 2013 Nov;28(11):889-926. (IF 5.3)
10. Gores GJ, **Darwish Murad S**, Heimbach JK, Rosen CB. *Liver transplantation for perihilar cholangiocarcinoma*. Dig Dis. 2013;31(1):126-9. Epub 2013 Jun 17. (IF 2.7)
11. **Darwish Murad S**, Heimbach JK, Gores GJ, Rosen CB, Benson JT, Kim WR. *Excellent quality of life after liver transplantation in patients with perihilar cholangiocarcinoma who have undergone neoadjuvant chemoradiation*. Liver Transpl. 2013 2013 May;19(5):521-8. doi: 10.1002/lt.23630. Epub 2013 Apr 9.(IF 3.9)
12. Smalberg JH, Koehler E, **Darwish Murad S**, Plessier A, Seijo S, Trebicka J, Primignani M, Rijken DC, de Maat MP, García-Pagán JC, Valla DC, Janssen HL, Leebeek FW; European Network for Vascular Disorders of the Liver (EN-Vie). *Fibrinogen γ' and variation in fibrinogen gamma genes in the etiology of portal vein thrombosis*. Thromb Haemost. 2013 Mar 5;109(3):558-60 (IF 6.1)
13. Seijo S, Plessier A, Hoekstra J, Dell'era A, Mandair D, Rifai K, Trebicka J, Morard I, Lasser L, Abalde JG, **Darwish Murad S**, Heller J, Hadengue A, Primignani M, Elias E, Janssen HL, Valla DC, Garcia-Pagan JC; For the European Network for Vascular Disorders of the Liver (EN-Vie). *Good long-term outcome of budd-chiari syndrome with a step-wise management*. Hepatology. 2013 Feb 6 Feb 6. doi: 10.1002/hep.26306. (IF 11.4)

14. Rijken DC, Kock EL, Guimarães AH, Talens S, **Darwish Murad S**, Janssen HL, Leebeek FW. *Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests.* J Thromb Haemost. 2012 Oct;10(10):2116-22 (IF 6.1)
15. Rosen CB, **Darwish Murad S**, Heimbach JK, Nyberg SL, Nagorney DM, Gores GJ. *Neoadjuvant therapy and liver transplantation for hilar cholangiocarcinoma: is pretreatment pathological confirmation of diagnosis necessary?* J Am Coll Surg. 2012 Jul;215(1):31-8; discussion 38-40.(if 3.7)
16. **Darwish Murad S**, Kim WR, Harnois DM, Douglas DD, Burton K, Kulik LM, Botha JF, Mezrich JD, Chapman WC, Schwartz JJ, Hong JC, Emond JC, Jeon H, Rosen CB, Gores GJ, Heimbach JK. *Efficacy of neoadjuvant chemoradiation followed by liver transplantation for perihilar cholangiocarcinoma at 12 US centers.* Gastroenterology. 2012 Jul; 143(1):88-98.e3. (IF 12.8)
17. **Darwish Murad S**, Kim WR, Therneau T, Gores GJ, Rosen CB, Martenson JA, Alberts SR, Heimbach JK. *Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma.* Hepatology. 2012 Sep;56(3):972-81. (IF 11.4)
18. Smalberg JH, Koehler E, **Darwish Murad S**, Plessier A, Seijo S, Trebicka J, Primignani M, de Maat MP, Garcia-Pagan JC, Valla DC, Janssen HL, Leebeek FW; European Network for Vascular Disorders of the Liver (EN-Vie). *The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis.* Blood. 2011 Apr 14;117(15):3968-73. Epub 2011 Mar 1. (IF 9.1)
19. Talens S, Hoekstra J, Dirx SP, **Darwish Murad S**, Trebicka J, Elias E, Primignani M, García-Pagán JC, Valla DC, Janssen HL, Leebeek FW, Rijken DC; EN-Vie Study Group. *Proteomic analysis reveals that apolipoprotein A1 levels are decreased in patients with Budd-Chiari syndrome.* J Hepatol. 2011 May;54(5):908-14. Epub 2011 Jan 14.(IF 9.6)
20. Hoekstra J, Guimarães AH, Leebeek FW, **Darwish Murad S**, Malfliet JJ, Plessier A, Hernandez-Guerra M, Langlet P, Elias E, Trebicka J, Primignani M, Garcia-Pagan JC, Valla DC, Rijken DC, Janssen HL; European Network for Vascular Disorders of the Liver (EN-Vie). *Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome.* Blood. 2010 Jan 14;115(2):388-95. Epub 2009 Nov 18. (IF 9.1)
21. Plessier A, **Darwish Murad S**, Hernandez-Guerra M, Consigny Y, Fabris F, Trebicka J, Heller J, Morard I, Lasser L, Langlet P, Denninger MH, Vidaud D, Condat B, Hadengue A, Primignani M, Garcia-Pagan JC, Janssen HL, Valla D; European Network for Vascular Disorders of the Liver (EN-Vie). *Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study.* Hepatology. 2010 Jan;51(1):210-8. (IF 11.4)
22. Hoekstra J, Leebeek FWG, Plessier A, Hernandez-Guerra M, **Darwish Murad S**, Heller J, Hadengue A, Elias E, Primignani M, Garcia-Pagan JC, Valla DC, Janssen HLA for the EN-Vie Study Group. *Paroxysmal nocturnal hemoglobinuria in Budd-Chiari Syndrome: Findings from a cohort study.* J Hepatol. 2009 Oct;51(4):696-706. Epub 2009 Jul 23.(IF 9.6)
23. **Darwish Murad S**, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, Trebicka J, Morard I, Lasser L, Heller J, Hadengue A, Langlet P, Miranda H, Primignani M, Elias E, Leebeek FW, Rosendaal FR, Garcia-Pagan JC, Valla DC, Janssen HL; EN-Vie (European Network for Vascular Disorders of the Liver). *Etiology, Management and Outcome of the Budd-Chiari Syndrome.* Ann Intern Med. 2009 Aug 4;151(3):167-75 (IF 16.7)
24. Garcia-Pagan JC, Heydtmann M, Raffa S, Plessier A, **Darwish Murad S**, Fabris F, Vizzini G, Albraldes JG, Olliff S, Nicolini A, Luca A, Primignani M, Janssen HLA, Valla D, Elias E, Bosch J. *TIPS for Budd-Chiari syndrome: long-term results and prognostic factors in 124 patients.* Gastroenterology 2008;135(3):808-15 (IF 12.8)
25. **Darwish Murad S**, Dom VAL, Ritman EL, de Groen PC, Beighley BE, Abraham SC, Zondervan PE, Janssen HLA. *Early changes of the portal tract on Micro-CT images in a newly developed ratmodel for Budd-Chiari Syndrome.* J Gastroenterology and Hepatology, 2008 Oct;23(10):1561-6 (IF 3.3)
26. **Darwish Murad S**, Luong TK, Pattynama PM, Hansen BE, van Buuren HR, Janssen HL. *Long-term outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt in Budd-Chiari syndrome.* Liver Int 2008;28(2):249-56 (IF 3.8)
27. Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, Cazals-Hatem D, Plessier A, Garcia-Pagan JC, **Darwish Murad S**, Raffa S, Janssen HLA, Gardin C, Cereja S, Tonetti C, Giraudier S, Condat B, Casadeval N, Fenauz P, Valla D. *The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases.* Blood 2008;111(10):4922-9 (IF 9.1)
28. Spaander MC, **Darwish Murad S**, van Buuren HR, Hansen BE, Kuipers EJ, Janssen HL. *Endoscopic treatment of esophagogastric variceal bleeding in patients with noncirrhotic*

- extrahepatic portal vein thrombosis: a long-term follow-up study.* *Gastrointestinal endoscopy* 2008;67(6):821-7 (IF 6.7)
29. **Darwish Murad S**, Kamath PS. *Liver transplantation for Budd-Chiari syndrome: when is it really necessary?* *Liver Transpl* 2008;14(2):133-5
 30. **Darwish Murad S**, Kim WR, de Groen PC, Kamath PS, Malinchoc M, Valla DC, Janssen HLA. *Can the model for end-stage liver disease be used to predict the prognosis in patients with Budd-Chiari syndrome?* *Liver Transpl* 2007;13(6):867-74 (IF 3.9)
 31. De Bruijne ELE, **Darwish Murad S**, de Maat MP, Tank MW, Haagsma EB, van Hoek B, Rosendaal FR, Janssen HLA, Leebeek FWG for the Liver and Thrombosis Study Group. *Genetic Variation in Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) is Associated with the Risk of Splanchnic Vein Thrombosis.* *Thrombosis and Haemostasis*, 2007;97(2): 181-5 (IF 6.1)
 32. Smalberg JH, **Darwish Murad S**, Braakman E, Valk PJ, Janssen HLA, Leebeek FWG. *Myeloproliferative Disease in the Pathogenesis and Survival of Budd-Chiari Syndrome.* *Haematologica*, 2006; 91(12): 1712-3 (IF 6.4)
 33. **Darwish Murad S**, Janssen HLA. *Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2.* *N Engl J Med* 2006;355:737-738; author reply 738
 34. **Darwish Murad S**, Valla DC, Groen de PC, Zeitoun G, Haagsma EZ, Kuipers EJ, Janssen HLA. *Pathogenesis and Treatment of Budd-Chiari syndrome combined with Portal Vein Thrombosis.* *Am J Gastro* 2006;101:83-90 (IF 7.5)
 35. **Darwish Murad S**, Janssen HLA. *Transjugular Intrahepatic Portosystemic Shunt (TIPS), the preferred therapeutic option for Budd-Chiari Syndrome associated with portal vein thrombosis.* *Am J Gastro*, 2006; 101: author reply 2164-2165
 36. Van Zonneveld M, Honkoop P, Niesters HGM, **Darwish Murad S**, de Man RA, Schalm SW, Janssen HLA. *Response to alpha-interferon prolongs survival in chronic hepatitis B. Results from long-term follow-up after alpha-interferon.* *Hepatology*, 2004; 39 (3): 804-810 (IF 11.4)
 37. **Darwish Murad S**, Valla DC, Groen de PC, Zeitoun G, Hopmans JC, Haagsma EZ, Hoek van B, Hansen B, Hop WC, Rosendaal FR, Janssen HLA. *Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome.* *Hepatology*, 2004; 39(2): 500-508 (IF 11.4)
 38. **Darwish Murad S**, Joung IMA, van Lenthe FJ, Bengi-Arslan L, Crijnen AAM. *Determinants of Self-reported Emotional and Behavioral Problems in Turkish Immigrant Adolescents of Age 11 to 18.* *Soc Psychiatry Psychiatr Epidemiol*, 2004; 39 (3): 196-207 (IF 2.7)
 39. **Darwish Murad S**, Joung IMA, van Lenthe FJ, Bengi-Arslan L, Crijnen AAM. *Predictors of Self-reported Problem Behaviour in Turkish immigrant and Dutch Adolescents in the Netherlands.* *J of Child Psychol Psych*, 2003; 44 (3): 412-423 (IF 5.4)